Skip to main content

ANALISIS DEL EXOMA EN PACIENTES AZOOSPERMICOS CON BLOQUEO DE LA ESPERMATOGENESIS: DESARROLLO DE UN PANEL GENICO CON VALOR DIAGNOSTICO Y PRONOSTICO PRE-BIOPSIA TESTICULAR

PI20/01562

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2020
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO
Execution centre IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Genetic determinants of testicular sperm extraction outcomes, insights from a large multicentre study of men with non-obstructive azoospermia

  • Riera-Escamilla, Antoni|||0000-0002-4485-3094
  • Arafa, Mohamed M.
  • Farnetani, Ginevra
  • Xavier, Miguel|||0000-0003-0709-7223
  • Oud, Manon S.|||0000-0001-9513-3030
  • Majzoub, Ahmad A.
  • Ramos, Liliana|||0000-0002-4269-013X
  • Abrardo, Chiara|||0000-0002-9577-6025
  • Spinelli, Matilde|||0009-0009-4820-4620
  • Moreno-Mendoza, Daniel
  • Defazio, Giuseppe|||0000-0002-9356-5224
  • Ars, Elisabet|||0000-0002-4118-4358
  • Pybus, Marc|||0000-0002-6195-5738
  • Sánchez-Curbelo, Josvany|||0000-0002-6489-3309
  • Elbardisi, Haitham|||0000-0003-3902-7924
  • Nawaz, Shoaib
  • Syed, Najeeb
  • Ruiz-Castañé, Eduardo|||0000-0002-7469-4610
  • van der Heijden, Godfried W.
  • Fakhro, Khalid A.
  • Veltman, Joris A.|||0000-0002-3218-8250
  • Krausz, Csilla|||0000-0001-6748-8918
What is the diagnostic yield and the pre-testicular sperm extraction (TESE) prognostic value of a non-obstructive azoospermia (NOA)-specific virtual gene panel? The diagnostic yield in our cohort was 6.1%, and by combining our data with published literature, we identified 11 genes compatible with testicular sperm production and 19 genes associated with no sperm retrieval in carriers of pathogenic (P) or likely pathogenic (LP) mutations. Azoospermia, the most severe form of male infertility, affects ∼1% of the male population, with TESE being the primary treatment option. However, in NOA, TESE fails in nearly 50% of cases and existing clinical parameters are unable to predict TESE failure. Over the past decade, next-generation sequencing (NGS) has identified several candidate NOA genes, but their diagnostic utility and impact on TESE outcomes have not been fully explored. A literature search was addressed to identify well-established NOA genes for designing a specific virtual gene panel for NOA. Our retrospective study analysed the diagnostic yield of the NGS-based virtual gene panel, comprising 145 genes, in 571 men affected by idiopathic NOA with known TESE outcomes. Subsequently, a second literature search was performed to identify carriers of LP/P variants in the genes where we identified mutations, focusing on individuals with known TESE outcomes. This approach allowed us to integrate the published data with our findings and predict a genotype-phenotype correlation between the affected genes and TESE success. 571 NOA patients with known TESE outcomes were recruited in two European and one Middle East centres. Variants were obtained from a whole-exome sequencing dataset and crossed with the 145 genes of the virtual gene panel. After a filtering process, variants were manually assessed and classified according to ACMG guidelines by using two methods: (i) In order to compare our data with previously published studies, we applied ACMG-AMP guidelines along with ClinGen recommendations used by other similar studies. (ii) A new approach was used to optimize ACMG-AMP guidelines with all ClinGen recommendations and incorporated NOA-specific rules addressing phenotypic, locus, and allelic heterogeneity. LP and P variants were confirmed by Sanger sequencing. By using the new variant classification approach adapted for NOA, we identified LP/P variants in 6.1% of patients, with a higher yield (9.4%) in cases with negative TESE outcomes and maturation arrest (11.7%). By integrating our findings with the literature, we highlight 19 genes recurrently associated with negative TESE outcomes and 11 genes associated with positive sperm retrieval either in the testis or in semen. TESE is recommended for patients with LP or P variants in the 11 specific genes. Notably, six of these genes are located on the X chromosome, therefore, these variants will be obligatorily transmitted to daughters, and potentially increase the risk of NOA-related infertility in male offspring. We observed that nine genes, in which we identified LP/P variants, have been previously described in individuals with premature ovarian insufficiency (POI). Of these, eight were associated with negative TESE outcomes in men. Furthermore, we propose seven additional genes mutated in our cohort of NOA patients as novel POI candidates. These genes have not yet been considered as POI candidates, but they result in female infertility when knocked out in mouse models. LP/P variants have been submitted to ClinVar (). NOA is genetically heterogeneous, and our panel excludes those genes which were reported only in a single subject or single family. Although this can limit the diagnostic yield in our study, it ensures that only genes with clear relationship with NOA have been analysed. While in our cohort TESE outcomes are known for all patients, this information is often not available for mutation carriers in the published studies. Consequently, the total number of patients with P variants in the same gene remains relatively low, limiting our final conclusions. However, even if the number of carriers of genes associated with positive sperm retrieval is relatively low, it does not constrain our conclusions regarding TESE prediction. On the other hand, caution is warranted for genes linked to negative TESE outcomes, except for TEX11, SYCE1, and MSH4, each of which have 10 or more reported TESE-negative cases. Our study was performed on the largest available NOA cohort with known TESE outcomes. It not only provides an estimate on the diagnostic potential of a NOA-specific virtual gene panel, but it also advances the understanding of genetic factors influencing TESE outcomes. Half of the genes mutated in our study and presenting TESE-positive outcomes are already informative for clinical decision-making. The observed genotype-phenotype correlations may help in personalized decision-making prior to TESE, in order to undergo the procedure or to avoid unnecessary invasive treatment. It provides valuable insights that can inform clinical management strategies and potentially offer personalized treatments based on genetic profiles. The use of two different variant classification methods highlights that previous studies may have over-estimated the diagnostic yield, underscoring the need for a standardized variant classification approach addressed specifically to male infertility. Our study also emphasizes the overlap between NOA- and POI-associated genes, which has important clinical implications for genetic counselling of female siblings of affected individuals. This work was funded by the Spanish Ministry of Health Instituto Carlos III-FIS FONDOS FEDER (grant numbers PI20/01562 and PI23/00425) and the Fanconi Research Fund awarded to C.K. and A.R.-E. This article is based upon work from COST Action CA20119 (ANDRONET), supported by COST (European Cooperation in Science and Technology) (). C.K., A.R.-E., G.F., M.J.X., M.S.O., C.A., M.S., and E.R.-C. are members of the Action. This research was also supported by the Qatar National Research Fund (QNRF) under grant NPRP12S-0318-190394, and by an Investigator Award in Science from the Wellcome Trust (209451 to J.A.V.). The authors declare no competing interests.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Diverse monogenic subforms of human spermatogenic failure

  • Nagirnaja, Liina|||0000-0003-1948-2495
  • Lopes, Alexandra M.|||0000-0003-3539-2318
  • Charng, Wu-Lin
  • Miller, Brian
  • Stakaitis, Rytis|||0000-0001-5946-1731
  • Golubickaite, Ieva|||0000-0003-2739-8576
  • Stendahl, Alexandra|||0000-0002-2977-4806
  • Luan, Tianpengcheng
  • Friedrich, Corinna
  • Mahyari, Eisa
  • Fadial, Eloise|||0000-0001-8889-6718
  • Kasak, Laura|||0000-0003-4182-2396
  • Vigh-Conrad, Katinka
  • Oud, Manon S.|||0000-0001-9513-3030
  • Xavier, Miguel|||0000-0003-0709-7223
  • Cheers, Samuel R.
  • James, Emma R.
  • Guo, Jingtao|||0000-0002-0159-5021
  • Jenkins, Timothy G.
  • Riera-Escamilla, Antoni|||0000-0002-4485-3094
  • Barros, Alberto|||0000-0002-8700-3698
  • Carvalho, Filipa|||0000-0001-9546-4614
  • Fernandes, Susana
  • Gonçalves, João|||0000-0001-9359-8774
  • Gurnett, Christina A.
  • Jørgensen, Niels|||0000-0003-4827-0838
  • Jezek, Davor|||0000-0002-1528-5462
  • Jungheim, Emily S.
  • Kliesch, Sabine|||0000-0002-7561-4870
  • McLachlan, Robert I.|||0000-0003-4637-3876
  • Omurtag, Kenan R.
  • Pilatz, Adrian|||0000-0001-8072-1841
  • Sandlow, Jay I.
  • Smith, James
  • Eisenberg, Michael L.|||0000-0001-5482-0141
  • Hotaling, James M.|||0000-0002-4401-4565
  • Jarvi, Keith A.|||0000-0001-6966-9114
  • Punab, Margus
  • Rajpert-De Meyts, Ewa|||0000-0002-5946-7559
  • Carrell, Douglas T.|||0000-0002-6471-2803
  • Krausz, Csilla|||0000-0001-6748-8918
  • Laan, Maris|||0000-0002-8519-243X
  • O'Bryan, Moira Kathleen|||0000-0001-7298-4940
  • Schlegel, Peter N.|||0000-0002-7129-8137
  • Tüttelmann, Frank|||0000-0003-2745-9965
  • Veltman, Joris A.|||0000-0002-3218-8250
  • Almstrup, Kristian|||0000-0002-1832-0307
  • Aston, Kenneth I.
  • Conrad, Donald F.|||0000-0003-3828-8970
Non-obstructive azoospermia (NOA) is the most severe form of male infertility and typically incurable. Defining the genetic basis of NOA has proven challenging, and the most advanced classification of NOA subforms is not based on genetics, but simple description of testis histology. In this study, we exome-sequenced over 1000 clinically diagnosed NOA cases and identified a plausible recessive Mendelian cause in 20%. We find further support for 21 genes in a 2-stage burden test with 2072 cases and 11,587 fertile controls. The disrupted genes are primarily on the autosomes, enriched for undescribed human "knockouts", and, for the most part, have yet to be linked to a Mendelian trait. Integration with single-cell RNA sequencing data shows that azoospermia genes can be grouped into molecular subforms with synchronized expression patterns, and analogs of these subforms exist in mice. This analysis framework identifies groups of genes with known roles in spermatogenesis but also reveals unrecognized subforms, such as a set of genes expressed across mitotic divisions of differentiating spermatogonia. Our findings highlight NOA as an understudied Mendelian disorder and provide a conceptual structure for organizing the complex genetics of male infertility, which may provide a rational basis for disease classification. The GEMINI consortium sequenced 1,000 cases of idiopathic male infertility and identified a plausible Mendelian cause in 20% of cases. The infertility genes can be grouped by expression pattern, facilitating their interpretation and follow-up.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

A systematic review of the validated monogenic causes of human male infertility, 2020 update and a discussion of emerging gene-disease relationships

  • Houston, Brendan J.|||0000-0002-1078-756X
  • Riera-Escamilla, Antoni|||0000-0002-4485-3094
  • Wyrwoll, Margot J.
  • Salas-Huetos, Albert|||0000-0001-5914-6862
  • Xavier, Miguel|||0000-0003-0709-7223
  • Nagirnaja, Liina|||0000-0003-1948-2495
  • Friedrich, Corinna
  • Conrad, Donald F.|||0000-0003-3828-8970
  • Aston, Kenneth I.
  • Krausz, Csilla|||0000-0001-6748-8918
  • Tüttelmann, Frank|||0000-0003-2745-9965
  • O'Bryan, Moira Kathleen|||0000-0001-7298-4940
  • Veltman, Joris A.|||0000-0002-3218-8250
  • Oud, Manon S.|||0000-0001-9513-3030
Background: Human male infertility has a notable genetic component, including well-established diagnoses such as Klinefelter syndrome, Y-chromosome microdeletions and monogenic causes. Approximately 4% of all infertile men are now diagnosed with a genetic cause, but a majority (60-70%) remain without a clear diagnosis and are classified as unexplained. This is likely in large part due to a delay in the field adopting next-generation sequencing (NGS) technologies, and the absence of clear statements from field leaders as to what constitutes a validated cause of human male infertility (the current paper aims to address this). Fortunately, there has been a significant increase in the number of male infertility NGS studies. These have revealed a considerable number of novel gene-disease relationships (GDRs), which each require stringent assessment to validate the strength of genotype-phenotype associations. To definitively assess which of these GDRs are clinically relevant, the International Male Infertility Genomics Consortium (IMIGC) has identified the need for a systematic review and a comprehensive overview of known male infertility genes and an assessment of the evidence for reported GDRs. Objective and Rationale: In 2019, the first standardised clinical validity assessment of monogenic causes of male infertility was published. Here, we provide a comprehensive update of the subsequent 1.5 years, employing the joint expertise of the IMIGC to systematically evaluate all available evidence (as of 1 July 2020) for monogenic causes of isolated or syndromic male infertility, endocrine disorders or reproductive system abnormalities affecting the male sex organs. In addition, we systematically assessed the evidence for all previously reported possible monogenic causes of male infertility, using a framework designed for a more appropriate clinical interpretation of disease genes. Search Methods: We performed a literature search according to the PRISMA guidelines up until 1 July 2020 for publications in English, using search terms related to 'male infertility' in combination with the word 'genetics' in PubMed. Next, the quality and the extent of all evidence supporting selected genes were assessed using an established and standardised scoring method. We assessed the experimental quality, patient phenotype assessment and functional evidence based on gene expression, mutant in-vitro cell and in-vivo animal model phenotypes. A final score was used to determine the clinical validity of each GDR, across the following five categories: no evidence, limited, moderate, strong or definitive. Variants were also reclassified according to the American College of Medical Genetics and Genomics-Association for Molecular Pathology (ACMG-AMP) guidelines and were recorded in spreadsheets for each GDR, which are available at imigc.org. Outcomes: The primary outcome of this review was an overview of all known GDRs for monogenic causes of human male infertility and their clinical validity. We identified a total of 120 genes that were moderately, strongly or definitively linked to 104 infertility phenotypes. Wider Implications: Our systematic review curates all currently available evidence to reveal the strength of GDRs in male infertility. The existing guidelines for genetic testing in male infertility cases are based on studies published 25 years ago, and an update is far overdue. The identification of 104 high-probability 'human male infertility genes' is a 33% increase from the number identified in 2019. The insights generated in the current review will provide the impetus for an update of existing guidelines, will inform novel evidence-based genetic testing strategies used in clinics, and will identify gaps in our knowledge of male infertility genetics. We discuss the relevant international guidelines regarding research related to gene discovery and provide specific recommendations to the field of male infertility. Based on our findings, the IMIGC consortium recommend several updates to the genetic testing standards currently employed in the field of human male infertility, most important being the adoption of exome sequencing, or at least sequencing of the genes validated in this study, and expanding the patient groups for which genetic testing is recommended.